Selected Papers in This Issue
|
 |
Academia-Pharma Intersect: Providing a Broader Perspective on Drug Development Synergies between Academia and Industry Bruce A. Chabner (p. 1) |
|
Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer Joel W. Neal (p. 3) |
|
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside Jordi Rodon, Jose Perez, Razelle Kurzrock (p. 37) |
|
The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development Cathy Eng (p. 73) |
|
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib Bruno Vincenzi, Daniele Santini, Antonio Russo, Raffaele Addeo, Francesco Giuliani, Liliana Montella, Sergio Rizzo, Olga Venditti, Anna Maria Frezza, Michele Caraglia, Giuseppe Colucci, Salvatore Del Prete, Giuseppe Tonini (p. 85) |
|
Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review Madelon Pijls-Johannesma, Janneke P.C. Grutters, Frank Verhaegen, Philippe Lambin, Dirk De Ruysscher (p. 93) |
|
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma Jeff Summers, Martin H. Cohen, Patricia Keegan, Richard Pazdur (p. 104) |
|
|
|
